Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients

被引:0
作者
Chuanying Geng
Guangzhong Yang
Huixing Zhou
Huijuan Wang
Yanchen Li
Yun Leng
Zhiyao Zhang
Yuan Jian
Wenming Chen
机构
[1] Capital Medical University,Department of Hematology, Beijing Chaoyang Hospital
来源
Clinical and Experimental Medicine | 2023年 / 23卷
关键词
Multiple myeloma; Barthel index; Survival; Prognostic factors;
D O I
暂无
中图分类号
学科分类号
摘要
The basic activities of daily life may affect the prognosis of multiple myeloma (MM) patients and the Barthel index (BI) is currently the most widely used tool to evaluate basic activities of daily life, but few studies have evaluated its prognostic value in MM. We retrospectively enrolled patients with newly diagnosed MM and analyzed the association between the BI and the survival of newly diagnosed MM patients. We totally analyzed 538 patients and found that median overall survival (OS) and progression-free survival (PFS) were significantly shorter in the low BI (≤ 85) group compared with the high BI (> 85) group. Univariate Cox proportional hazards regression analysis showed that the low BI was associated with shorter OS and PFS. It was also confirmed that the low BI was poor prognostic factor for OS and PFS in multivariable analyses. In the propensity score matching analysis, patients with low BI also had shorter OS and PFS. Our study suggested that the low BI was a poor prognostic factor for patients with newly diagnosed MM.
引用
收藏
页码:2593 / 2600
页数:7
相关论文
共 113 条
  • [1] Cowan AJ(2022)Diagnosis and management of multiple myeloma: a review JAMA 327 464-477
  • [2] Green DJ(2022)Current approaches to management of newly diagnosed multiple myeloma Am J Hematol 97 S3-S25
  • [3] Kwok M(2022)Promising therapeutic approaches for relapsed/refractory multiple myeloma Hematology 27 343-352
  • [4] Lee S(2021)Disease heterogeneity, prognostication and the role of targeted therapy in multiple myeloma Leuk Lymphoma 62 3087-3097
  • [5] Coffey DG(2015)Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report Blood 125 2068-2074
  • [6] Holmberg LA(2019)Performance of the International Myeloma Working Group myeloma frailty score among patients 75 and older J Geriatr Oncol 33 648-657
  • [7] Goel U(2020)A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial Leukemia 34 224-233
  • [8] Usmani S(2014)International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Lancet Oncol 15 e538-e548
  • [9] Kumar S(2006)International uniform response criteria for multiple myeloma Leukemia 20 1467-1473
  • [10] Ni B(2022)Chimeric antigen receptor T-cells, bispecific antibodies, and antibody-drug conjugates for multiple myeloma: an update Am J Hematol 97 99-118